Research
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d1309 (Published 17 March 2011) Cite this as: BMJ 2011;342:d1309
Related articles
- Editorial Published: 17 March 2011; BMJ 342 doi:10.1136/bmj.d1354
- Information In Practice Published: 28 March 1998; BMJ 316 doi:10.1136/bmj.316.7136.989
- Paper Published: 01 March 2003; BMJ 326 doi:10.1136/bmj.326.7387.472
- Research Published: 19 August 2009; BMJ 339 doi:10.1136/bmj.b2942
- News Published: 29 September 2010; BMJ 341 doi:10.1136/bmj.c5333
- Research Published: 19 March 2010; BMJ 340 doi:10.1136/bmj.c1344
- Analysis Published: 06 September 2011; BMJ 343 doi:10.1136/bmj.d4849
- Research Published: 05 February 2020; BMJ 368 doi:10.1136/bmj.l7078
See more
- StatinsBMJ January 24, 2024, 384 e072584; DOI: https://doi.org/10.1136/bmj-2022-072584
- Proton pump inhibitorsBMJ November 13, 2023, 383 e070752; DOI: https://doi.org/10.1136/bmj-2022-070752
- Recognition and initial management of ovarian torsionBMJ April 28, 2023, 381 e074514; DOI: https://doi.org/10.1136/bmj-2022-074514
- Aortic stenosisBMJ March 15, 2023, 380 e070511; DOI: https://doi.org/10.1136/bmj-2022-070511
- Human monkeypox: diagnosis and managementBMJ February 06, 2023, 380 e073352; DOI: https://doi.org/10.1136/bmj-2022-073352
Cited by...
- Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
- PPAR{gamma} agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation
- Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes
- Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association
- Metformin, but Not Rosiglitazone, Attenuates the Increasing Plasma Levels of a New Cardiovascular Marker, Fibulin-1, in Patients With Type 2 Diabetes
- Intramyocardial Adiposity After Myocardial Infarction: New Implications of a Substrate for Ventricular Tachycardia
- Interpreting Adverse Signals in Diabetes Drug Development Programs
- Deficiency of TDAG51 Protects Against Atherosclerosis by Modulating Apoptosis, Cholesterol Efflux, and Peroxiredoxin-1 Expression
- Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats
- Insulin Resistance: Metabolic Mechanisms and Consequences in the Heart
- PPAR-{gamma} as a therapeutic target in cardiovascular disease: evidence and uncertainty: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- Production of 7-O-Methyl Aromadendrin, a Medicinally Valuable Flavonoid, in Escherichia coli
- Imaging of Pharmacologic Intervention: Decoding Therapeutic Mechanism or Defining Effectiveness?
- Evidence of comparative efficacy should have a formal role in European drug approvals
- Authors' reply
- Demonisation of rosiglitazone
- Rosiglitazone vs. Pioglitazone -- What Are the Odds?
- What have we learnt from the rosiglitazone saga?